RTS Life Science International
http://www.rts-group.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RTS Life Science International
Astex's Pyramid Scheme
Astex's latest deal with Schering further distances the firm from infrastructure-heavy structural biology players. Astex hopes that by applying its fragment-based approach to solving key discovery problems among a handful of much sought-after targets-rather than solving many target structures or offering its capability on a service basis-it can sign higher value deals and prevent itself from becoming a victim of the field's commoditization.
Recent Dealmaking (06/2003)
Summarizing the month in European dealmaking.
Practical Dealmaking in Discovery: The Structural Biology Case
Discovery dealmaking is by no means dead-but it's certainly been practicalized. In the last few months, one good example of a still interesting discovery area--high-throughput structural biology--has seen a flurry of dealmaking. But it's not yet frequent or rich enough to justify the venture valuations originally applied to them. And the deals themselves reflect the results-oriented conservatism of Big Pharma buyers.
Company Information
- Industry
- Services
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice